VAS
CRNX

Vestmark Advisory Solutions’s Crinetics Pharmaceuticals CRNX Stock Holding History

Vestmark Advisory Solutions’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.82M Hold
48,724
– – 0.02% 754
2026
Q1 		$1.77M Buy
48,724
+2,172
+5% +$97K 0.02% 673
2025
Q4 		$2.17M Buy
+46,552
New +$2.07M 0.03% 554

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vestmark Advisory Solutions's CRNX Position: Q2 2026 in Review

Vestmark Advisory Solutions held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 48,724 shares worth $1.82M. The position accounts for 0.02% of the portfolio, ranked #754.

Vestmark Advisory Solutions first reported a position in CRNX in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.17M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Vestmark Advisory Solutions held 48,724 shares of Crinetics Pharmaceuticals worth $1.82M as of Q2 2026.
  • Vestmark Advisory Solutions left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up 0.02% of Vestmark Advisory Solutions's portfolio in Q2 2026, its #754 holding.
  • Vestmark Advisory Solutions first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Vestmark Advisory Solutions's Crinetics Pharmaceuticals position peaked at $2.17M in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Vestmark Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.